Boston Scientific Announces $700M Restructuring Plan Amid WATCHMAN Sales Slump

Boston Scientific has announced a comprehensive restructuring plan aimed at generating significant long-term savings, a strategic move that comes as the company grapples with a sharp stock decline ahead of its second-quarter earnings report. The plan, approved by the board on July 27, is designed to streamline operations after a slowdown in sales of a key product erased more than half of the company's market value over the past year.

Details of the Restructuring

The plan anticipates total pre-tax charges of $700 million to $800 million and is expected to be substantially complete by the end of 2029. Boston Scientific projects the initiative will yield approximately $500 million in annualized savings upon completion.

Key components of the estimated charges include:

• $300 million to $350 million for production and supply chain optimization.
• $275 million to $300 million for employee termination benefits.
• $125 million to $150 million for other costs related to functional transformation.

The company stated it plans to reinvest a substantial portion of these savings into growth initiatives rather than direct shareholder returns, signaling a focus on long-term recovery.

Context: WATCHMAN Woes and Market Reaction

Ad

The restructuring follows a severe downturn in Boston Scientific's stock (BSX), which has fallen 57% from its September 2025 peak. The decline was triggered by management warnings of flat sequential U.S. sales for its flagship WATCHMAN left atrial appendage closure device, citing physician workflow constraints and reimbursement challenges.

This single product-line issue has weighed heavily on investor sentiment, prompting at least seven analyst firms to cut their price targets in July alone. Compounding these concerns, the FDA recently issued an alert regarding a catheter tip separation risk for the company's ENROUTE device, leading to a product lot recall.

Outlook: All Eyes on Q2 Earnings

While the restructuring plan addresses the cost side of the business, investors are focused on the upcoming Q2 earnings release on July 29 for an update on the company's revenue outlook. The report will be critical in determining whether the slowdown in WATCHMAN sales is stabilizing or worsening.

Despite the stock's performance, Wall Street analysts have largely maintained their positive ratings, with 26 'Buy' ratings and a consensus price target of approximately $72.25, according to the source material. The key test will be whether management reaffirms its full-year organic growth guidance of 6.5% to 8.0% or is forced to issue a downward revision.